Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hampel

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Carcinogenesis|December 1, 2021
Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancersLiam L Donnelly, Tyler C Hogan, Sean M Lenahan, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 2, 2025
A pilot study to determine the feasibility and safety of pharmacist and nurse driven management of venetoclax ramp-up in patients with chronic lymphocytic leukemiaRachel J Bailen, Monica I Aasum, Linda M Tamminga, et al.
British Journal of Haematology|July 16, 2022
Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemiaPaul J Hampel, Kari G Rabe, Timothy G Call, et al.
Blood Advances|March 27, 2024
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemiaPaul J Hampel, Mahesh Swaminathan, Kerry A Rogers, et al.
Leukemia & Lymphoma|April 25, 2019
Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practicePaul J Hampel, Wei Ding, Timothy G Call, et al.
Leukemia & Lymphoma|May 26, 2020
Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practiceAmber B Koehler, Nelson Leung, Timothy G Call, et al.
The Oncologist|September 5, 2020
Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic LeukemiaPaul J Hampel, Timothy G Call, Kari G Rabe, et al.
Blood|January 9, 2024
Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signatureSalma B Abdelbaky, Brian Giacopelli, Kari G Rabe, et al.
Medrxiv : the Preprint Server for Health Sciences|June 4, 2026
Genetic risk and immune dysregulation of classic Hodgkin lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma: a multicentric studyMingfei Yan, Sameer A Parikh, Michelly K Sampaio De Melo, et al.
British Journal of Haematology|August 18, 2018
Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centrePaul J Hampel, Melissa C Larson, Brian Kabat, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Carcinogenesis|December 1, 2021
Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancersLiam L Donnelly, Tyler C Hogan, Sean M Lenahan, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 2, 2025
A pilot study to determine the feasibility and safety of pharmacist and nurse driven management of venetoclax ramp-up in patients with chronic lymphocytic leukemiaRachel J Bailen, Monica I Aasum, Linda M Tamminga, et al.
British Journal of Haematology|July 16, 2022
Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemiaPaul J Hampel, Kari G Rabe, Timothy G Call, et al.
Blood Advances|March 27, 2024
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemiaPaul J Hampel, Mahesh Swaminathan, Kerry A Rogers, et al.
Leukemia & Lymphoma|April 25, 2019
Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practicePaul J Hampel, Wei Ding, Timothy G Call, et al.
Leukemia & Lymphoma|May 26, 2020
Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practiceAmber B Koehler, Nelson Leung, Timothy G Call, et al.
The Oncologist|September 5, 2020
Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic LeukemiaPaul J Hampel, Timothy G Call, Kari G Rabe, et al.
Blood|January 9, 2024
Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signatureSalma B Abdelbaky, Brian Giacopelli, Kari G Rabe, et al.
Medrxiv : the Preprint Server for Health Sciences|June 4, 2026
Genetic risk and immune dysregulation of classic Hodgkin lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma: a multicentric studyMingfei Yan, Sameer A Parikh, Michelly K Sampaio De Melo, et al.
British Journal of Haematology|August 18, 2018
Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centrePaul J Hampel, Melissa C Larson, Brian Kabat, et al.
Pageof 9